Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1)

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 3, 2011, Pages 222-229

  McNicholas, Paul M ^a   Mann, Paul A ^a   Bsc, Lisa Wojcik ^a   Phd, Ping Qiu ^a   Lee, Erin ^a   McCarthy, Michael ^a   Shen, Junwu ^a   Black, Todd A ^a   Strizki, Julie M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

clonal analysis; HIV 1; resistance; tropism; vicriviroc

Indexed keywords

GLYCOPROTEIN GP 160; PLACEBO; VICRIVIROC; VIRUS RNA;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG BLOOD LEVEL; GENE MAPPING; GENETIC ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PHYLOGENY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIROGENESIS; VIRUS ENVELOPE; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; PIPERAZINES; PYRIMIDINES; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT FAILURE;

EID: 79951810774     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ff63ee     Document Type: Article

References (20)

1. Berger EA, Murphy PM, and Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Ann Rev Immunol. 1999;17:657-700. (Pubitemid 29241137)
2. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 Activity. Antimicrob Agents Chemother. 2005;49:4721-4732. (Pubitemid 41552605)
3. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol. 2008;73:789-800. (Pubitemid 351397884)
4. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:4911-4919. (Pubitemid 41782160)
5. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology. 2007;361:212-228. (Pubitemid 46551222)
6. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359-2371.
7. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology. 2008;373:387-399.
8. McNicholas P, Wei Y, Whitcomb J, et al. Characterization of emergent HIV resistance in treatment naive subjects enrolled in a vicriviroc phase 2 trial. J Infect Dis. 2010;201:1470-1480.
9. Suleiman J, Zingman BS, Diaz RS, et al. Vicriviroc in combination therapy with an optimized regimen for treatment experienced subjects: 48 week results of the VICTOR-E1 phase 2 trial. J Infect Dis. 2010;201: 590-599.
10. Tsibris AMN, Sagar M, Gulick RM, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol. 2008;82:8210-8214.
11. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008;198:1113-1122.
12. Strizki JM, Xu S, Wagner NE, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-infection in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98:12718-12723. (Pubitemid 33020012)
13. Sing T, Low AJ, Beerenwinkle N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther. 2007;12: 1097-1106. (Pubitemid 350114990)
14. Jensen MA, Li F-S, van't Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003;77:13376-13388. (Pubitemid 37494331)
15. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566-575. (Pubitemid 46185274)
16. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-4920.
17. Reeves JD, Coakley E, Petropoulos CJ, et al. An enhanced-sensitivity TrofileTM HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry. 2009;3:94-102.
18. Ogert RA, Hou Y, Ba L, et al. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5. Virology. 2010;400:145-155.
19. Goetz MB, Leduc R, Kostman JR, et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr. 2009;50:259-266.
20. Cleo G, Anastassopoulou CG, Ketas TJ, et al. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc Natl Acad Sci USA. 2009;106:5318-5323.